Detalles de la búsqueda
1.
Real-world glycated haemoglobin changes among type 2 diabetes mellitus patients treated with a maintenance dose of 7 mg or 14 mg of oral semaglutide.
Diabetes Obes Metab
; 26(6): 2111-2118, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38418411
2.
Once-weekly glucagon-like peptide-1 receptor agonists vs dipeptidyl peptidase-4 inhibitors: cardiovascular effects in people with diabetes and cardiovascular disease.
Cardiovasc Diabetol
; 22(1): 319, 2023 11 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-37985992
3.
Early experiences of nusinersen for the treatment of spinal muscular atrophy: Results from a large survey of patients and caregivers.
Muscle Nerve
; 63(3): 311-319, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33184859
4.
Insights into the early use of oral semaglutide in routine clinical practice: The IGNITE study.
Diabetes Obes Metab
; 23(9): 2177-2182, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34060209
5.
Real-World Treatment Patterns Among Patients with Type 2 Diabetes Mellitus Initiating Treatment with Oral Semaglutide.
Diabetes Ther
; 2024 May 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-38722496
6.
Real-World Hemoglobin A1c Changes, Prescribing Provider Types, and Medication Dose Among Patients with Type 2 Diabetes Mellitus Initiating Treatment with Oral Semaglutide.
Adv Ther
; 40(11): 5102-5114, 2023 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37740832
7.
Increased Healthcare Resource Use and Costs After Discontinuation of Liraglutide in Patients with Type 2 Diabetes from a Commercial- and Medicaid-Insured Claims Database.
Diabetes Ther
; 13(11-12): 1861-1874, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36239850
Resultados
1 -
7
de 7
1
Próxima >
>>